
    
      This is a Phase 2, open-label, nonrandomized, multicenter, monotherapy study in subjects with
      histologically documented MCL who have relapsed after â‰¥ 1 (but not > 5) prior treatment
      regimens. All subjects meeting eligibility criteria will receive PCI-32765 capsules at a
      dosage of 560 mg/day once daily for a 28-day cycle until disease progression, unacceptable
      toxicity, or enrollment in a long-term extension study, whichever occurs earlier.
    
  